NEW YORK – A patent infringement lawsuit filed against Qiagen related to the Wi-Fi connectivity feature of its automated nucleic acid isolation instrument platform has been voluntarily dismissed by the plaintiff.
In a Tuesday filing with the US District Court for the District of Delaware, Triumph IP provided notice of its voluntary dismissal of the lawsuit, which it originally filed in November in the same court. The suit alleged that Qiagen's EZ2 Connect platform infringed on a US patent claiming a process of associating an apparatus to a communication network in a way that avoids interference with other networks.
Triumph IP has filed lawsuits against at least 10 different companies in different industries alleging infringement of the patent.
Qiagen launched the EZ2 Connect platform last April. It uses pre-filled cartridges and magnetic bead technology for fully automated processing of up to 24 samples in parallel in as little as 20 minutes. A central feature of the system is its ability to connect to Qiagen's QiaSphere digital laboratory ecosystem that enables remote features such as instrument management and real-time status reporting.
Qiagen plans to launch a version of the platform specifically for molecular diagnostics this year.